 therapeutic index antineoplastic drugs combination intracellular histamine antagonists L-Histidinol protein synthesis inhibitor structural analogue L-histidine chemotherapy-treated mice cytoprotective normal stem cells cytotoxicity cells phenylmethyl phenoxy ethanamine.HCl DPPE antagonist microsomal nuclear intracellular histamine receptors mediation proliferation modulation prostaglandin synthesis DPPE cytotoxic cells vitro cytoprotective gut vivo similar pharmacologic profiles histidinol DPPE structural resemblance histidinol histamine intracellular histamine receptors important action histidinol differential effect DPPE histidinol normal malignant cells DPPE histidinol host cells effects chemotherapy tumor cell vivo histidinol intracellular histamine receptors isolated microsomes nuclei affinity DPPE Nevertheless agent potency intracellular histamine receptors potency DNA protein synthesis cytotoxicity normal mitogen-stimulated murine lymphocytes mouse human breast cancer cells demonstrated histidinol g/kg DPPE mg/kg murine bone marrow progenitors doxorubicin fluorouracil doses mg/kg antitumor activity doxorubicin daunorubicin murine models early cancer postulate effects intracellular histamine receptor intracellular histamine mediates DNA protein synthesis downward modulation growth-inhibitory prostaglandin levels Antagonism intracellular action histamine intracellular histamine receptors DPPE histidinol differential perturbations growth/eicosanoid metabolism normal malignant cells basis new approach